{"id":5143,"date":"2025-09-15T13:51:58","date_gmt":"2025-09-15T11:51:58","guid":{"rendered":"https:\/\/cvja.co.za\/journal\/?p=5143"},"modified":"2026-05-05T13:58:02","modified_gmt":"2026-05-05T11:58:02","slug":"cvja-2025-058","status":"publish","type":"post","link":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/","title":{"rendered":"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction"},"content":{"rendered":"
\r\n
\r\n
\r\n \r\n \r\n\u00c7a\u011fr\u0131 Zorlu, Ya\u011fmur Demirezen, Sefa Erdi \u00d6m\u00fcr, Cemal K\u00f6seo\u011flu \r\n <\/div> \r\n<\/div> \r\n
\r\n Copyright:<\/strong> Clinics Cardive Publishing (Pty) Ltd. publisher\r\n of Cardiovascular Journal of Africa.<\/div>\r\n
<\/div> \r\n
\r\n
\r\n Abstract \r\n <\/div> \r\n \r\n
\r\n \r\n \r\n \r\n \r\n Background:<\/strong> \r\n \r\n No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow. \r\n
\r\n \r\n Methods:<\/strong> \r\n \r\n Between 2018 and 2024, 2382 patients with STEMI, who underwent percutaneous coronary intervention (PCI), were included. The patients were divided into two groups according to whether no-reflow developed or not, and the relationships between the SII and TyG, as well as their combined use in the prediction of no-reflow, were evaluated. Receiver operating curve (ROC) analyses were performed to predict the development of no-reflow. \r\n
\r\n \r\n Results:<\/strong> \r\nIn the ROC analyses, the cut-off values of SII and TyG for best predicting no-reflow were 421 and 7.82, respectively. Using the combination of these two markers was the most powerful predictor of no-reflow risk when included in a single variable, such as high SII or high TyG. Furthermore, the co-presence of a high SII and a high TyG showed the highest specificity (84%) and sensitivity (85%) for no-reflow\r\n
\r\n \r\n \r\n Conclusion:<\/strong> \r\n \r\nThe combination of the SII and TyG, simple and cost-effective risk assessments, may be a more reliable prognostic indicator of the development of no-reflow in STEMI patients undergoing PCI than the use of the SII and TyG alone. \r\n
\r\n\r\n \r\n <\/div> \r\n <\/div> \r\n \r\n \r\n
\r\n \r\n Keywords:<\/strong> \r\n \r\n no-reflow, systemic immune-inflammatory index, triglyceride-glucose index, ST-elevation myocardial infarction<\/strong> \r\n \r\n <\/div> \r\n \r\n
\r\n \r\n Submitted:<\/strong> March 18, 2025; \r\n Accepted:<\/strong> April 24, 2025; \r\n Published:<\/strong> September 15, 2025
\r\n Cardiovasc J Afr 2025; 36<\/b>: 388-395<\/em>\r\n
Volume 36, Issue 3<\/strong>
\r\n <\/div> \r\n \r\n
\r\n DOI Citation Reference: dx.doi.org\/10.5830\/CVJA-2025-058 \r\n <\/div> \r\n \r\n
\r\n \r\n Department of Cardiology, Tokat Gaziosmanpasa University Hospital, Tokat, Turkey\r\n<\/strong>
\r\n\u00c7a\u011fr\u0131 Zorlu
\r\nYa\u011fmur Demirezen
\r\nSefa Erdi \u00d6m\u00fcr\r\n

\r\n\r\n Department of Cardiology, Alanya Alaaddin Keykubat University Hospital, Antalya, Turkey\r\n\r\n<\/strong>
\r\nCemal K\u00f6seo\u011flu\r\n\r\n

\r\n \r\n\r\n [soshsc hide=\"logged\"]\r\n You need to be logged in to view and download<\/a> the full text PDF version. Register for a free account?<\/a><\/strong>

[\/soshsc]\r\n \r\n \r\n \r\n <\/div>\r\n \r\n<\/div>","protected":false},"excerpt":{"rendered":"

No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[44,107],"tags":[],"class_list":["post-5143","post","type-post","status-publish","format-standard","hentry","category-cardiovascular-topics","category-volume-36-issue-3"],"yoast_head":"\nEvaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction - Cardiovascular Journal of Africa<\/title>\n<meta name=\"description\" content=\"No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction - Cardiovascular Journal of Africa\" \/>\n<meta property=\"og:description\" content=\"No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/\" \/>\n<meta property=\"og:site_name\" content=\"Cardiovascular Journal of Africa\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T11:51:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T11:58:02+00:00\" \/>\n<meta name=\"author\" content=\"Jaco Moolman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jaco Moolman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/\",\"url\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/\",\"name\":\"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction - Cardiovascular Journal of Africa\",\"isPartOf\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\"},\"datePublished\":\"2025-09-15T11:51:58+00:00\",\"dateModified\":\"2026-05-05T11:58:02+00:00\",\"author\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\"},\"description\":\"No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cvja.co.za\/journal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\",\"url\":\"https:\/\/cvja.co.za\/journal\/\",\"name\":\"Cardiovascular Journal of Africa\",\"description\":\"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvja.co.za\/journal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\",\"name\":\"Jaco Moolman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"caption\":\"Jaco Moolman\"},\"url\":\"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction - Cardiovascular Journal of Africa","description":"No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/","og_locale":"en_US","og_type":"article","og_title":"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction - Cardiovascular Journal of Africa","og_description":"No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.","og_url":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/","og_site_name":"Cardiovascular Journal of Africa","article_published_time":"2025-09-15T11:51:58+00:00","article_modified_time":"2026-05-05T11:58:02+00:00","author":"Jaco Moolman","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jaco Moolman","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/","url":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/","name":"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction - Cardiovascular Journal of Africa","isPartOf":{"@id":"https:\/\/cvja.co.za\/journal\/#website"},"datePublished":"2025-09-15T11:51:58+00:00","dateModified":"2026-05-05T11:58:02+00:00","author":{"@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920"},"description":"No-reflow is a phenomenon of unclear pathophysiology that occurs in approximately 5-10% of patients after primary percutaneous coronary intervention. Recently, the relationship between the systemic immune- inflammatory index (SII), which reflects inflammatory status, and the triglyceride-glucose index (TyG), which reflects insulin resistance, as well as heart disease and its complications, has been under investigation. In this study, we aimed to evaluate the ability of a combination of the SII and TyG, routinely obtained at admission, to identify ST-segment elevation myocardial infarction (STEMI) patients at risk of no-reflow.","breadcrumb":{"@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvja.co.za\/journal\/cvja-2025-058\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-058\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cvja.co.za\/journal\/"},{"@type":"ListItem","position":2,"name":"Evaluation of systemic immune inflammation and triglyceride\/glucose indices in the development of no-reflow in ST elevation myocardial infarction"}]},{"@type":"WebSite","@id":"https:\/\/cvja.co.za\/journal\/#website","url":"https:\/\/cvja.co.za\/journal\/","name":"Cardiovascular Journal of Africa","description":"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvja.co.za\/journal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920","name":"Jaco Moolman","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","caption":"Jaco Moolman"},"url":"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/"}]}},"_links":{"self":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/comments?post=5143"}],"version-history":[{"count":1,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5143\/revisions"}],"predecessor-version":[{"id":5510,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5143\/revisions\/5510"}],"wp:attachment":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/media?parent=5143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/categories?post=5143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/tags?post=5143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}